Early endpoints for acute bacterial skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2221-2222

  Drusano, George L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; SULFANILAMIDE;

BACTERIAL SKIN DISEASE; BACTERIAL TRANSMISSION; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; SKIN STRUCTURE; STATISTICAL ANALYSIS;

AZTREONAM; BIOLOGICAL MARKERS; CEPHALOSPORINS; FEMALE; HUMANS; MALE; SKIN DISEASES, BACTERIAL; VANCOMYCIN;

EID: 84860197284     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00157-12     Document Type: Note

References (7)

1. Ambrose PG, et al. 2012. Frequentist and Bayesian pharmacometric-based approach to facilitate critically needed new antibiotic development: Overcoming lies, damn lies and statistics. Antimicrob. Agents Chemother. 56:1466-1470.
2. Bhavnani SM, et al. 2011. Pharmacokinetic-pharmacodynamic analysis for efficacy of BC 3781 using new clinical trial endpoints in patients with acute bacterial skin and skin-structure infections, abstr. A2-025. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
3. Corey GR, et al. 2010. Integrated analysis of CANVAS 1 and 2: phase 3, multi-center, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51:641-650.
4. Friedland HD, et al. 2012. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 56:2231-2236.
5. Snodgrass WR, Anderson T. 1937. Sulphanilamide in the treatment of erysipelas. Br. Med. J. 2:1156-1159.
6. Snodgrass WR, Anderson T. 1937. Prontosil in the treatment of erysipelas. Br. Med. J. 2:101-104.
7. U.S. Food and Drug Administration. 2010. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. U.S. Food and Drug Administration, Rockville, MD.